Your session is about to expire
← Back to Search
Psoriasis Longitudinal Assessment and Registry (PSOLAR Trial)
N/A
Waitlist Available
Research Sponsored by Janssen Scientific Affairs, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8 years of follow up for each patient
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.
Eligible Conditions
- Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 8 years of follow up for each patient
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8 years of follow up for each patient
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events and Serious Adverse Events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Janssen Scientific Affairs, LLCLead Sponsor
164 Previous Clinical Trials
563,957 Total Patients Enrolled
4 Trials studying Psoriasis
232 Patients Enrolled for Psoriasis
Janssen Scientific Affairs, LLC Clinical TrialStudy DirectorJanssen Scientific Affairs, LLC
36 Previous Clinical Trials
70,381 Total Patients Enrolled